Document is current
Any future updates will be listed below
-
Authors
Gautam, Nina J.
Jimenez, Nicole R.
Łaniewski, Paweł
Cui, Haiyan
Roe, Denise J.
Chase, Dana M.
Herbst-Kralovetz, Melissa M. https://orcid.org/0000-0002-8540-5917
-
Funding
Funding for this research was provided by:
Mary Kay Ash Foundation (017–48)
Valley Research Partnership Grant (VRP26)
Phoenix Friends Foundation of University of Arizona Cancer Center (Phoenix Friends Foundation of University of Arizona Cancer Center)
Division of Cancer Prevention, National Cancer Institute (U54CA143924)
- License Information
-
More Information
Article History
Accepted: 10 July 2025
First Online: 19 July 2025
Declarations
:
: This study was approved by the Institutional Review Board at the University of Arizona (IRB no. 1708726047) and performed in accordance with the Declaration of Helsinki and federal guidelines. All participants provided written informed consent to participate in the study.
: Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dr. Herbst-Kralovetz (mherbst1@arizona.edu).
: This study did not generate any new unique reagents.
: M.M.H.-K is a paid consultant for Freya Biosciences. D.M.C. reports personal fees from Astra Zeneca, Eisai, GSK, Immunogen, and Merck. None of this work related to, was shared with, or was licensed to these companies or any other commercial entity. All other authors declare no competing interests.
